Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles for the co-delivery of DOX/CPT-PEG for targeting HepG2 cells
Author
Sánchez García, David
Borrós i Gómez, Salvador
Fornaguera Puigvert, Cristina
Martínez Edo, Gabriel
Other authors
Universitat Ramon Llull. IQS
Publication date
2020-11Abstract
A pH-triggered mesoporous silica nanoparticle (MSN)-based nano-vehicle for the dual delivery of doxorubicin (DOX)/camptothecin-PEG (CPT-PEG) has been prepared. To enhance its selectivity, the nanoparticles were decorated with glycyrrhetinic acid (GA) to target HepG2 cells. The highly insoluble CPT was derivatized with a reductive-cleavable PEG chain to improve its loading within the MSN. The preparation of these particles consisted of four steps. First, CPT-PEG was loaded within the pores of the MSN. Then, dihydrazide polyethylene glycol chains were introduced onto the surface of an aldehyde-functionalized MSN by means of a hydrazone bond. Afterwards, DOX was covalently attached to the other end of the dihydrazide polyethylene glycol chains. Finally, the resulting nanoparticles were decorated with GA by formation of an imine bond between the amino group of DOX and a benzaldehyde-GA derivative. The system was stable at physiological conditions and the release of both drugs was negligible. However, at acidic pH, a burst release of DOX and a gradual release of CPT-PEG takes place. GA-decorated drug delivery systems (DDS) selectively internalizes into HepG2. In vitro tests demonstrated that this system shows a great cytotoxicity towards HepG2 cells. Furthermore, glutathione cleavage of CPT prodrug assures the formation of free CPT leading to a synergistic effect in combination with DOX.
Document Type
Article
Published version
Language
English
Subject (CDU)
539 - Physical nature of matter
616 - Pathology. Clinical medicine
Keywords
Nanopartícules
Doxorubicina
Medicaments
Càncer
Mesoporous silica nanoparticles
Dual release
Doxorubicin
Camptothecin
Anticancer drugs
Combination therapy
Targeting systems
Pages
17 p.
Publisher
MDPI
Is part of
Pharmaceutics. Vol.12, n.11 (2020), 1048
Grant agreement number
info:eu-repo/grantAgreement/MCIU/PN I+D/RTI2018-094734-B-C22
info:eu-repo/grantAgreement/SUR del DEC/SGR/2017-SGR-01559
This item appears in the following Collection(s)
Rights
© L'autor/a
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/